drugset / Trial / NCT07594912

Teprotumumab N01 Versus Methylprednisolone After Urgent Orbital Decompression for Dysthyroid Optic Neuropathy

NCT07594912

Phase 2 Not yet recruiting 60 enrolled Sun Yat-sen University
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to evaluate the efficacy and safety of sequential Teprotumumab N01 compared with intravenous methylprednisolone (IVMP) after urgent orbital decompression in patients with dysthyroid optic neuropathy (DON).

Timeline

Start
2026-08
Primary completion
2027-12
Completion
2028-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Methylprednisolone Other / unclassified 0.5 g Intravenous
Comparator Methylprednisolone Other / unclassified 1 g Intravenous
Subject Teprotumumab Monoclonal antibody 20 mg/kg Intravenous